The Effect of Induction Chemotherapy with VEGF Inhibition on Tumor Response in Synchronously Metastasized Potentially Resectable Colorectal Cancer.
colorectal cancer
synchronous liver metastases
targeted therapy
tumor regression grading
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 May 2023
24 May 2023
Historique:
received:
31
03
2023
revised:
13
05
2023
accepted:
19
05
2023
medline:
10
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
(1) Background: The pathological tumor response of the primary tumor to induction chemotherapy in synchronously metastasized colorectal cancer (mCRC) patients has not been investigated. The aim of this study was to compare patients treated with induction chemotherapy combined with vascular endothelial growth factor (VEGF) or with epidermal growth factor receptor (EGFR) antibodies. (2) Methods: We present a retrospective analysis, where we included 60 consecutive patients with potentially resectable synchronous mCRC who received induction chemotherapy combined with either VEGF or EGFR antibodies. The primary endpoint of this study was the regression of the primary tumor, which was assessed by the application of the histological regression score according to Rödel. The secondary endpoints were recurrence-free survival (RFS) and overall survival (OS). (3) Results: A significantly better pathological response and a longer RFS for patients treated with the VEGF antibody therapy compared to those treated with the EGFR antibodies was demonstrated (
Identifiants
pubmed: 37296862
pii: cancers15112900
doi: 10.3390/cancers15112900
pmc: PMC10252058
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet Oncol. 2014 May;15(6):601-11
pubmed: 24717919
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Lancet Oncol. 2013 Nov;14(12):1208-15
pubmed: 24120480
Cancer. 2007 Dec 15;110(12):2761-7
pubmed: 17960603
J Clin Oncol. 2008 Apr 10;26(11):1830-5
pubmed: 18398148
Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21
pubmed: 10493478
Lancet Oncol. 2015 Oct;16(13):1306-15
pubmed: 26338525
Ann Oncol. 1999 Jun;10(6):623-6
pubmed: 10442182
Cancers (Basel). 2018 Sep 07;10(9):
pubmed: 30205529
JAMA. 2009 Dec 2;302(21):2338-44
pubmed: 19952320
J Clin Oncol. 2023 Mar 10;41(8):1541-1552
pubmed: 36657089
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Ann Surg Oncol. 2010 Nov;17(11):2870-6
pubmed: 20567921
J Clin Oncol. 2021 Apr 1;39(10):1098-1107
pubmed: 33560877
JAMA. 2017 Jun 20;317(23):2392-2401
pubmed: 28632865
Lancet Oncol. 2016 Oct;17(10):1426-1434
pubmed: 27575024
ACS Appl Mater Interfaces. 2022 Mar 9;14(9):11078-11091
pubmed: 35196008
Cancers (Basel). 2022 Nov 09;14(22):
pubmed: 36428606
Br J Cancer. 2013 Jun 25;108(12):2549-56
pubmed: 23703247
Ann Oncol. 2015 Apr;26(4):702-708
pubmed: 25538173
Virchows Arch. 2018 Feb;472(2):175-186
pubmed: 28918544
J Clin Oncol. 2020 Aug 20;:JCO2001225
pubmed: 32816630
BMC Cancer. 2015 Jul 10;15:511
pubmed: 26156156
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Eur J Cancer. 2023 May;184:106-116
pubmed: 36913832
Eur J Surg Oncol. 2015 Jul;41(7):868-74
pubmed: 25865557
Ann Oncol. 2023 Jan;34(1):10-32
pubmed: 36307056
J Clin Oncol. 2009 Jul 10;27(20):3379-84
pubmed: 19487380
J Clin Oncol. 2005 Dec 1;23(34):8688-96
pubmed: 16246976
Lancet Oncol. 2012 Nov;13(11):1152-60
pubmed: 23017669
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
JAMA Surg. 2021 Dec 1;156(12):1093-1101
pubmed: 34613339